Sodium selenate corrects glucose tolerance and heart function in STZ diabetic rats.
Sodium selenate, administered intraperitoneally (i.p.), resulted in an improvement in glucose tolerance in treated diabetic rats. Fed rat plasma glucose levels were reduced by selenate treatment in streptozotocin diabetic rats. The lowest values of blood glucose were reached within 3 weeks of beginning the treatment. Food and fluid consumption was reduced in treated compared to untreated diabetic rats. Diabetic treated rats did not release insulin in response to a glucose challenge and insulin release in response to a challenge was markedly reduced in control treated rats. Assessment of heart function using a working heart apparatus showed that treated diabetic rats with improved blood glucose levels had normal heart function at 8 weeks of diabetes in contrast to hearts from non-treated diabetics. This study extends previous observations on the in vivo insulin-like effects of sodium selenate.
Battell
M L
ML
Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Delgatty
H L
HL
McNeill
J H
JH
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D009202:Cardiomyopathies / Q000503:physiopathology; D048909:Diabetes Complications; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D006321:Heart / Q000187:drug effects*; D006334:Heart Function Tests / Q000187:drug effects; D007328:Insulin / Q000378:metabolism; D008055:Lipids / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D064586:Selenic Acid; D018036:Selenium Compounds / Q000494:pharmacology*; D014639:Vanadium / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D018036:Selenium Compounds; D014639:Vanadium; D064586:Selenic Acid; D005947:Glucose